Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 4, 2022 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 56 new employees with a grant date of August 1, 2022, as equity inducement awards outside of the…

Click here to view original post